An update on the pathogenic role of IL-6 in rheumatic diseases-Reference-Cited by-同舟云学术

An update on the pathogenic role of IL-6 in rheumatic diseases

Published:2021-10 Issue: Volume:146 Page:155645
ISSN:1043-4666
Container-title:Cytokine
language:en
Short-container-title:Cytokine

Author:

Kaneko Yuko,Takeuchi Tsutomu

Publisher

Elsevier BV

Subject

Molecular Biology,Hematology,Biochemistry,Immunology,Immunology and Allergy

Reference137 articles.

1. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response;Kishimoto;J Immunol.,1973

2. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin;Hirano;Nature,1986

3. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor;Yamasaki;Science,1988

4. Molecular cloning and expression of an IL-6 signal transducer, gp130;Hibi;Cell,1990

5. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001;Petty;J Rheumatol.,2004

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The immune pathology of bursitis in rheumatic inflammatory diseases, degenerative conditions and mechanical stress: A systematic review;Seminars in Arthritis and Rheumatism;2024-10

2. Advancements in the study of IL-6 and its receptors in the pathogenesis of gout;Cytokine;2024-10

3. IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization;Frontiers in Immunology;2024-08-20

4. The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout;2024-07-12

5. Safety, Pharmacokinetics, Preliminary Efficacy, Pharmacodynamics, and Immunogenicity of QX002N, an Anti-IL-17A Monoclonal Antibody, after Short-term Treatment of Active Ankylosing Spondylitis;2024-06-25